Sei Investments Co. Makes New $814,000 Investment in Aclaris Therapeutics, Inc. $ACRS

Sei Investments Co. acquired a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 217,154 shares of the biotechnology company’s stock, valued at approximately $814,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ACRS. Invesco Ltd. increased its position in shares of Aclaris Therapeutics by 409.0% during the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 45,864 shares during the period. Millennium Management LLC boosted its position in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after acquiring an additional 2,175,101 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aclaris Therapeutics by 29.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 127,366 shares during the period. Geode Capital Management LLC grew its holdings in shares of Aclaris Therapeutics by 108.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after acquiring an additional 1,282,042 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Aclaris Therapeutics by 25.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 623,792 shares of the biotechnology company’s stock worth $886,000 after acquiring an additional 125,071 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Trading Up 0.3%

ACRS stock opened at $5.86 on Friday. The stock’s 50 day simple moving average is $5.24 and its 200 day simple moving average is $4.38. Aclaris Therapeutics, Inc. has a 12-month low of $1.67 and a 12-month high of $6.51. The stock has a market capitalization of $819.35 million, a PE ratio of -10.10 and a beta of 0.78.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. On average, research analysts predict that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ACRS has been the subject of a number of research analyst reports. Oppenheimer assumed coverage on Aclaris Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating and a $10.00 target price for the company. Wedbush increased their price objective on Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Guggenheim began coverage on Aclaris Therapeutics in a research report on Tuesday, May 5th. They set a “buy” rating and a $12.00 price objective for the company. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Lifesci Capital started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $13.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of “Buy” and a consensus price target of $11.50.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.